Functional Labeling and Product Expansion for Imida Peptide
First written in FY2016. 10 of 26 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2024-Q3.
9 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「In the health supplement business, since March 2009 we have marketed Imida Peptide, a product developed through the Fatigue Quantification and Anti-Fatigue Food and Pharmaceutical Development Project. In addition to the flagship beverage, the product lineup includes a wide variety of products such as soft capsules and tablets.」
The company is reaffirming the product lineup for Imida Peptide, centered on beverages, soft capsules and tablets. - FY2024-Q2RestatedAnnual report
「In the health supplement business, since March 2009 we have marketed Imida Peptide, a product developed through the Fatigue Quantification and Anti-Fatigue Food and Pharmaceutical Development Project. In addition to the flagship beverage, the product lineup includes a wide variety of products such as soft capsules and tablets.」
The company is reaffirming the product lineup for Imida Peptide, centered on beverages, soft capsules and tablets. - FY2024-Q1RestatedAnnual report
「In the health supplement business, since March 2009 we have marketed Imida Peptide, a product developed through the Fatigue Quantification and Anti-Fatigue Food and Pharmaceutical Development Project. In addition to the flagship beverage, the product lineup includes a wide variety of products such as soft capsules and tablets.」
The company is reaffirming the product lineup for Imida Peptide, centered on beverages, soft capsules and tablets. - FY2023RestatedAnnual report
「In the health supplement business, since March 2009 we have marketed Imida Peptide, a product developed through the Fatigue Quantification and Anti-Fatigue Food and Pharmaceutical Development Project. In addition to the flagship beverage, the product lineup includes a wide variety of products such as soft capsules and tablets.」
The company is reaffirming the product lineup for Imida Peptide, centered on beverages, soft capsules and tablets. - FY2023-Q3RestatedAnnual report
「In the health supplement business, since March 2009 we have marketed Imida Peptide, a product developed through the Fatigue Quantification and Anti-Fatigue Food and Pharmaceutical Development Project. In addition to the flagship beverage, the product lineup includes a wide variety of products such as soft capsules and tablets.」
The company is reaffirming the product lineup for Imida Peptide, centered on beverages, soft capsules and tablets. - FY2023-Q2RestatedAnnual report
「In the health supplement business, since March 2009 we have marketed Imida Peptide, a product developed through the Fatigue Quantification and Anti-Fatigue Food and Pharmaceutical Development Project. In addition to the flagship beverage, the product lineup includes a wide variety of products such as soft capsules and tablets.」
The company is reaffirming the product lineup for Imida Peptide, centered on beverages, soft capsules and tablets. - FY2023-Q1RestatedAnnual report
「In the health supplement business, since March 2009 we have marketed Imida Peptide, a product developed through the Fatigue Quantification and Anti-Fatigue Food and Pharmaceutical Development Project. In addition to the flagship beverage, the product lineup includes a wide variety of products such as soft capsules and tablets.」
The company is reaffirming the broad Imida Peptide product lineup, including beverages, soft capsules and tablets. - FY2022-Q1RestatedAnnual report
「Since March 2009, we have marketed Imida Peptide, a product developed through the Fatigue Quantification and Anti-Fatigue Food and Pharmaceutical Development Project. In addition to the flagship beverage, the product lineup includes a wide variety of products such as soft capsules, tablets and sports drinks.」
The company is reaffirming the broad Imida Peptide product lineup, including beverages, soft capsules, tablets and sports drinks. - FY2021-Q3AdvancedAnnual report
「In the health supplement business, as in previous years, we concentrated advertising and promotional spending during the summer, when demand for fatigue recovery is high and responses to advertising are favorable, with the aim of further expanding sales. During the nine months ended 31 December, advertising and promotional spending was lower than in the corresponding period of the previous year. However, advertising efficiency improved because advertising was placed selectively in media with a high degree of certainty regarding cost effectiveness, among other factors, and revenue increased slightly year on year. In addition, operating income for the nine months ended 31 December increased substantially year on year, as revenue rose slightly despite reduced advertising and promotional spending, among other factors. As a result, the health supplement business reported revenue of ¥2,146 million, up 1.0% year on year, and operating income of ¥157 million, up 566.6% year on year.」
By reducing advertising and promotional expenses from the corresponding period of the previous year and selecting media with high cost effectiveness, revenue increased only marginally, but operating income came to ¥157 million, up 566.6% year on year. - FY2021-Q2Improved advertising efficiency and narrower operating lossAnnual report
「During the six months ended 30 September, advertising and promotional spending was lower than in the corresponding period of the previous year. However, advertising efficiency improved because advertising was placed selectively in media with a high degree of certainty regarding cost effectiveness, among other factors, and revenue increased slightly year on year. During the six months ended 30 September, expenses preceded revenue due to advertising and promotional spending and the application of discounts and free shipping to first-time purchasers, resulting in an operating loss. However, the operating loss narrowed year on year due in part to reduced advertising and promotional spending. As a result, the health supplement business reported revenue of ¥1,570 million, up 0.5% year on year, and an operating loss of ¥32 million, compared with an operating loss of ¥176 million in the corresponding period of the previous year.」
By selecting media with high cost effectiveness and controlling advertising and promotional expenses, revenue increased only marginally, but the operating loss narrowed from ¥176 million in the corresponding period of the previous year to ¥32 million. - FY2021-Q1Lower revenue but a narrower operating lossAnnual report
「During the first quarter of the current consolidated cumulative period, advertising expenditures were restrained compared with the same period of the previous year, but advertising efficiency improved because the company selectively placed advertisements in media with a high degree of certainty regarding cost-effectiveness, allowing it to maintain sales at roughly the previous year's level. As a result, the health supplements business reported net sales of ¥786 million (down 3.4% year on year) and an operating loss of ¥257 million (compared with an operating loss of ¥404 million in the same period of the previous year).」
By controlling advertising and promotional expenses and selecting media with high cost effectiveness, sales remained at approximately the same level as in the corresponding period of the previous year. Although revenue declined, the operating loss narrowed from ¥404 million to ¥257 million. - FY2020Full-year revenue and profit declineAnnual report
「In the current consolidated fiscal year, sales struggled because the number of new customers acquired, although sufficient to secure profitability, fell short of the assumptions underlying the plan, and advertising expenditures were restrained from the second quarter onward in light of first-quarter performance.」
The number of new customers acquired fell short of plan and advertising expenditures were restrained, causing sales to struggle. The health supplements business reported net sales of ¥2,665 million (down 4.9% year on year) and operating income of ¥168 million (down 35.5%). - FY2020-Q3Plan shortfalls continue, but operating profitability maintainedAnnual report
「In the third quarter of the current consolidated cumulative period, sales struggled because the number of new customers acquired, although sufficient to secure profitability, fell short of the assumptions underlying the plan, and advertising expenditures were restrained from the second quarter onward in light of first-quarter performance. Consequently, both net sales and operating income were below plan. The health supplements business therefore reported net sales of ¥2,124 million (down 3.1% year on year) and operating income of ¥23 million (down 79.4%).」
Sales struggled because the number of new customers acquired fell short of plan and advertising expenditures were restrained, resulting in lower net sales and a substantial decline in operating income. However, the business returned to operating profitability from the operating loss recorded in the second-quarter cumulative period. - FY2020-Q2Revenue decline and wider operating lossAnnual report
「As a result, expenses preceded sales because advertising expenditures were higher than in the same period of the previous year and discounts and free shipping were offered to first-time purchasers. In the second quarter of the current consolidated accounting period, sales struggled because the number of new customers acquired, although sufficient to secure profitability, fell short of the assumptions underlying the plan, and advertising expenditures were restrained in light of the first quarter's operating income falling short of plan. Consequently, both net sales and operating income were below plan.」
Sales struggled because advertising expenditures and other spending were restrained, and the health supplements business reported net sales of ¥1,562 million (down 3.5% year on year) and an operating loss of ¥176 million (compared with an operating loss of ¥95 million in the same period of the previous year). - FY2020-Q1Slightly higher net sales but substantially lower earningsAnnual report
「In the health supplements business, as in previous years, the company concentrated advertising expenditures during the summer season, when demand for fatigue recovery is high and responses to advertising are favorable, to further expand sales. As a result, expenses preceded sales because advertising expenditures were higher than in the same period of the previous year and discounts and free shipping were offered to first-time purchasers. Consequently, although net sales increased slightly year on year, earnings declined substantially and the operating loss widened in the first quarter of the current consolidated cumulative period.」
Although the company sought to expand sales through concentrated summer advertising, discounts for first-time purchasers and free shipping, net sales were ¥814 million, up only 0.4% year on year, while operating loss widened to ¥404 million. - FY2019AdvancedAnnual report
「As a result, the health supplements business reported net sales of ¥2,802 million (up 17.0% year on year) and operating income of ¥261 million (up 26.5%).」
Against a backdrop of more subscription customers and advertising campaigns, the health supplements business reported higher net sales and operating income for the full year. Despite the weakness in profitability, including upfront expenses through the previous quarter, full-year results showed progress toward earnings growth. - FY2019-Q3AdvancedAnnual report
「As in previous years, the business actively invested in advertising during the summer season, when demand for fatigue recovery is high and responses to advertising are favorable, with the aim of further expanding sales. In the third quarter of the current consolidated cumulative period, advertising expenditures were substantially higher than in the same period of the previous year, particularly during the summer, and active advertising campaigns were conducted, including television commercials and the use of talent, to further expand sales. As a result, sales remained on an expansionary trend, mainly owing to an increase in subscription customers and the effects of advertising campaigns. However, expenses preceded sales because advertising expenditures were substantially higher than in the same period of the previous year and discounts and free shipping were offered to first-time purchasers. Consequently, although net sales increased year on year, earnings declined. However, as the company is in the process of recovering upfront expenses through repeat purchases, there has been no material change in the assumptions underlying the full-year plan.」
Advertising expenditures were substantially increased, particularly during the summer, and television commercials and talent endorsements were used. As a result, health supplements business net sales were ¥2,193 million, up 21.0% year on year. However, operating income was ¥114 million, down 38.8%, as sales expansion and recovery of upfront expenses remained in progress. - FY2019-Q2AdvancedAnnual report
「As a result, sales remained on an expansionary trend owing in part to an increase in subscription customers and the effects of advertising campaigns, but expenses preceded sales because advertising expenditures were substantially higher than in the same period of the previous year and discounts and free shipping were offered to first-time purchasers. Consequently, although net sales increased year on year, earnings declined substantially and an operating loss was recorded in the second quarter of the current consolidated cumulative period. However, there has been no material change in the assumptions underlying the full-year plan, and the company expects to recover upfront expenses through repeat purchases, with expanding sales contributing to earnings.」
Sales expanded on the back of subscription customers and advertising, with health supplements business net sales of ¥1,618 million, up 24.5% year on year. However, an operating loss of ¥95 million was recorded as advertising and other expenses preceded sales, and the company expects to recover these costs through repeat purchases. - FY2019-Q1AdvancedAnnual report
「As a result, sales remained on an expansionary trend owing in part to an increase in subscription customers and the effects of advertising campaigns, but expenses preceded sales because advertising expenditures were substantially higher than in the same period of the previous year and discounts and free shipping were offered to first-time purchasers. Consequently, although net sales increased year on year, earnings declined substantially and the operating loss widened in the first quarter of the current consolidated cumulative period. However, there has been no material change in the assumptions underlying the full-year plan, and from the second quarter onward, the company expects to recover upfront expenses through repeat purchases, with expanding sales contributing to earnings.」
Sales expanded on the back of more subscription customers and advertising, with health supplements business net sales of ¥810 million, up 24.2% year on year. However, operating loss widened to ¥326 million as advertising and other expenses preceded sales, and the company expects to recover these costs through repeat purchases from the second quarter onward. - FY2018AdvancedAnnual report
「For the current consolidated fiscal year, sales remained on an expansionary trend, owing in part to an increase in subscription customers and the favorable effects of active advertising campaigns timed to the summer season, when demand for fatigue recovery is high. As a result, the health supplements business reported net sales of ¥2,396 million (up 20.4% year on year) and operating income of ¥206 million (up 4.2%).」
Against a backdrop of more subscription customers and summer advertising, the health supplements business centered on Imida Peptide reported higher net sales and operating income. - FY2018-Q3AdvancedAnnual report
「Sales during the third quarter of the current consolidated cumulative period remained on an expansionary trend, owing in part to an increase in subscription customers and the favorable effects of active advertising campaigns timed to the summer season, when demand for fatigue recovery is high. As a result, the health supplements business reported net sales of ¥1,812 million (up 19.8% year on year) and operating income of ¥187 million (up 3.0%).」
Against a backdrop of more subscription customers and summer advertising campaigns, the health supplements business reported higher net sales and operating income. - FY2018-Q2AdvancedAnnual report
「Sales during the second quarter of the current consolidated cumulative period remained on an expansionary trend, owing in part to an increase in subscription customers and the favorable effects of active advertising campaigns timed to the summer season, when demand for fatigue recovery is high. At the same time, expenses preceded sales as a result of advertising expenditures and discounts and free shipping for first-time purchasers. Consequently, although net sales increased, earnings struggled to grow. The company is in the process of recovering upfront expenses through repeat purchases and expects expanding sales to contribute further to earnings from the third quarter of the current consolidated accounting period onward. As a result, the health supplements business reported net sales of ¥1,300 million (up 20.8% year on year) and operating income of ¥38 million (down 20.4%).」
Sales expanded on the back of more subscription customers and summer advertising, with net sales up 20.8% year on year. Operating income declined year on year, but the company expects to recover upfront expenses through repeat purchases and see a growing earnings contribution from the third quarter onward. - FY2018-Q1AdvancedAnnual report
「Sales during the first quarter of the current consolidated cumulative period remained on an expansionary trend, owing in part to an increase in subscription customers and active advertising campaigns timed to the summer season, when demand for fatigue recovery is high and responses to advertising are favorable. At the same time, expenses preceded sales as a result of advertising expenditures and discounts and free shipping for first-time purchasers. Consequently, although net sales increased year on year, earnings declined and an operating loss was recorded. However, both net sales and earnings were broadly on plan, and from the second quarter onward, the company expects to recover the upfront expenses through repeat purchases, with expanding sales contributing to earnings.」
Sales expanded on the back of an increase in subscription customers and summer advertising, with net sales of ¥652 million (up 21.9% year on year). However, operating loss widened to ¥109 million as advertising and other expenses preceded sales, and the company expects to recover these costs through repeat purchases from the second quarter onward. - FY2017-Q3AdvancedAnnual report
「Sales during the third quarter of the current consolidated cumulative period remained on an expansionary trend, owing in part to an increase in subscription customers and the favorable effects of active advertising campaigns timed to the summer season, when demand for fatigue recovery is high. As a result, the health supplements business reported net sales of ¥1,502 million (up 87.0% year on year) and operating income of ¥209 million (up 503.8%).」
Against a backdrop of more subscription customers and summer advertising campaigns, sales of health supplements including Imida Peptide expanded, with net sales and operating income substantially exceeding the same period of the previous year. - FY2017-Q1RestatedAnnual report
「In addition to the core beverage, we now offer a diverse product lineup including soft capsules, tablets and sports drinks.」
The product lineup for Imida Peptide continues to include beverages, soft capsules, tablets and sports drinks. - FY2016First statedAnnual report
「The notification for a food with function claims under the system introduced in April 2015 has been accepted, and the product may currently carry the functional claim that it 'reduces physical fatigue experienced in daily life.'」
The Group is commercializing the results of the Fatigue Project through the food-with-function-claims system and a product lineup including beverages, soft capsules and tablets.